• Amylyx Pharmaceuticals (NasdaqGS:AMLX) is advancing avexitide through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH).
• Pivotal Phase III data from LUCIDITY are expected next quarter.
• The company has also started a U.S. expanded access program so certain PBH patients can receive avexitide before any potential approval.

Amylyx Pharmaceuticals focuses on therapies for serious neurological and metabolic conditions, with avexitide as its lead candidate for PBH. PBH can be a difficult complication after bariatric surgery, and treatment options are limited, so new data on avexitide may draw attention from both clinicians and investors. The current Phase III work puts the company in the spotlight within the PBH treatment space.

With pivotal data on the horizon, Amylyx is preparing for a possible commercial launch of avexitide, subject to any future FDA decisions. The launch of an expanded access program suggests the company is prioritizing patient demand while it waits for Phase III readouts and any regulatory review that may follow.

Stay updated on the most important news stories for Amylyx Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amylyx Pharmaceuticals.

Quick Assessment

• ✅ Price vs Analyst Target: At US$15.20, the stock trades about 35% below the US$23.30 consensus target.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 69.1% below fair value, indicating a large valuation gap.
• ❌ Recent Momentum: The 30 day return is roughly a 6.6% decline, showing recent weakness despite the PBH news.

There is only one way to know the right time to buy, sell or hold Amylyx Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Amylyx Pharmaceuticals's Fair Value.

Key Considerations

• 📊 Progress in the Phase III LUCIDITY trial and the new expanded access program both center the investment case on avexitide execution in PBH.
• 📊 Watch upcoming Phase III readout timing, any FDA interactions and how the company funds operations while it remains loss making.
• ⚠️ Revenue is currently close to zero and the company reported a net loss of about US$150.1m, so outcome and timing of avexitide are critical.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Amylyx Pharmaceuticals analysis. Alternatively, you can visit the community page for Amylyx Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.